Molecular Targeting Technologies Inc. (MTTI) today announced its collaboration with Bexion Pharmaceuticals, LLC to develop a novel nanovesicle for molecular imaging of tumors.

Bexion has shown that specific versions of the nanovesicles can be used to selectively target a broad range of tumors, both solid and hematologic. Also, specific formulations have demonstrated the potential for treatment of a wide range of human cancers, including gliomas, prostate and pancreatic cancer.

With the initial indication focused on gliomas, the companies seek to develop dual modality diagnostics using the technology.

“The ability to visualize the tumor by two imaging modalities offers a new approach for monitoring and accurate resection of tumors,” said Dr. Brian Gray, MTTI vice president of research.